You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Foundayo ™ (orforglipron) tablet
0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What is the incidence of hair loss with Foundayo™ (orforglipron)?
In ATTAIN-1 and ATTAIN-2, hair loss was reported more frequently in female than male participants in the orforglipron and placebo treatment groups. Hair loss adverse reactions in orforglipron-treated participants were associated with weight reduction.
See important safety information, including boxed warning, in the attached prescribing information.
Content Overview
- Was Hair Loss Reported With Orforglipron in Phase 3 Studies for Weight Management?
- What Is Known About Hair Loss in the Context of Body Weight Reduction?
- Enclosed Prescribing Information
- References
Was Hair Loss Reported With Orforglipron in Phase 3 Studies for Weight Management?
ATTAIN-1 and ATTAIN-2 were randomized, double-blind, placebo-controlled trials evaluating the efficacy and safety of orforglipron in adults with obesity or overweight. ATTAIN-1 enrolled participants without type 2 diabetes (T2D) and ATTAIN-2 enrolled participants with T2D.1,2
In the pooled ATTAIN-1 and ATTAIN-2 trials, 4-5% of participants experienced hair loss across the orforglipron study doses versus 2% of participants on placebo, with hair loss reported more frequently in female than male participants in both the orforglipron (7.0% female versus 0.9% male) and placebo (3.0% female versus 0.7% male) treatment groups.3
Hair loss adverse reactions in orforglipron-treated participants were associated with weight reduction.3
These studies were conducted with an investigational orforglipron capsule formulation at doses equivalent to the once-daily tablet dosages approved in the United States.1-3
Treatment Recommendation for Hair Loss
The ATTAIN-1 and ATTAIN-2 study protocols did not provide guidance about prevention or management of hair loss.1,2
Eli Lilly and Company cannot provide treatment recommendations related to hair loss. The health care practitioner may use
- the patient's prior medical history and concomitant medications, and
- other individual factors in developing a treatment plan.
The health care practitioner should consider potential risks and benefits of treatment options and monitor appropriately.
What Is Known About Hair Loss in the Context of Body Weight Reduction?
Weight reduction by various methods (lifestyle, surgery, medications) is associated with hair loss, usually transient.4-7
Telogen effluvium is thinning or shedding of the hair resulting from the early entry of hair into the telogen phase (the resting phase of the hair follicle), which commonly occurs after severe physical, emotional, or metabolic stress.4,7
Hair loss has been noted since the 1970s in patients rapidly losing weight via diets and is commonly described following bariatric surgery.6,7
Additionally, hair loss is described with glucagon-like peptide-1 (GLP-1) receptor agonist-induced weight reduction.5
Hair loss associated with weight reduction typically resolves on its own once weight loss stabilizes.4,6,7
Although this type of hair loss is widely considered an indirect effect of weight reduction, hair loss is considered an adverse drug reaction for some currently marketed weight management medications due to its meaningful impact on patient psychosocial and emotional well-being.8
Enclosed Prescribing Information
FOUNDAYO™ (orforglipron) tablets, for oral use, Lilly
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
- Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. https://doi.org/10.1056/NEJMoa2511774
- Horn DB, Ryan DH, Giljanovic Kis S, et al; ATTAIN-2 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025;406(10522):2927-2944. https://doi.org/10.1016/S0140-6736(25)02165-8.
- Foundayo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
- Telogen effluvium (a type of hair loss). British Association of Dermatologists. Updated May 2020. Accessed March 4, 2026. https://cdn.bad.org.uk/uploads/2021/12/29200250/Telogen-effluvium-Update-May-2020-lay-reviewed-March-2020.pdf
- Burke O, Sa B, Cespedes DA, et al. Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study. J Am Acad Dermatol. 2025;92(5):1141-1143. https://doi.org/10.1016/j.jaad.2025.01.046
- Zhang W, Fan M, Wang C, et al. Hair loss after metabolic and bariatric surgery: a systematic review and meta-analysis. Obes Surg. 2021;31(6):2649-2659. https://doi.org/10.1007/s11695-021-05311-2
- Goette DK, Odom RB. Alopecia in crash dieters. JAMA. 1976;235(24):2622-2623.
- Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: April 03, 2026